Joel Greenblatt Neurocrine Biosciences Inc Transaction History

Gotham Asset Management, LLC

$16.1 Billion
Q2 2025

A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Gotham Asset Management, LLC holds 91,129 shares of NBIX stock, worth $13.7 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

91,129

Previous 31,023 193.75%

Holding current value

$13.7 Million

Previous $3.43 Million 233.84%

% of portfolio

0.07%

Previous 0.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$87.54 - $128.18 $5.26 Million - $7.7 Million	60,106 Added 193.75%	91,129 $11.5 Million
Q1 2025 May 15, 2025	BUY	$107.22 - $153.29 $2.71 Million - $3.88 Million	25,309 Added 442.93%	31,023 $3.43 Million
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $1.07 Million - $1.34 Million	-9,603 Reduced 62.7%	5,714 $779,000
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $2.63 Million - $3.52 Million	-22,962 Reduced 59.99%	15,317 $1.76 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $4.32 Million - $4.72 Million	32,975 Added 621.7%	38,279 $5.27 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $30,513 - $33,635	-234 Reduced 4.23%	5,304 $731,000
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $50,913 - $63,724	480 Added 9.49%	5,538 $729,000
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $33,377 - $41,570	-355 Reduced 6.56%	5,058 $569,000
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $195,175 - $228,616	-2,180 Reduced 28.71%	5,413 $510,000
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $22,209 - $29,032	-236 Reduced 3.01%	7,593 $768,000
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $235,210 - $280,040	2,204 Added 39.18%	7,829 $935,000
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $2,668 - $3,126	29 Added 0.52%	5,625 $597,000
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $108,152 - $142,799	-1,427 Reduced 20.32%	5,596 $545,000
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $323,489 - $423,326	4,465 Added 174.55%	7,023 $658,000
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $203,744 - $271,710	2,558 New	2,558 $218,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $1.63 Million - $2.03 Million	-18,712 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $564,459 - $793,330	5,870 Added 45.71%	18,712 $1.8 Million
Q2 2020 Aug 13, 2020	SELL	$85.09 - $130.36 $541,427 - $829,480	-6,363 Reduced 33.13%	12,842 $1.57 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $785,650 - $1.19 Million	-10,460 Reduced 35.26%	19,205 $1.66 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $1.37 Million - $1.87 Million	15,730 Added 112.88%	29,665 $3.19 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $287,586 - $348,246	3,431 Added 32.66%	13,935 $1.26 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $637,734 - $805,731	-8,828 Reduced 45.67%	10,504 $887,000
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $204,880 - $270,562	2,956 Added 18.05%	19,332 $1.7 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $495,046 - $901,112	-7,246 Reduced 30.67%	16,376 $1.17 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $1.6 Million - $2.04 Million	16,209 Added 218.66%	23,622 $2.9 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $558,198 - $785,703	7,413 New	7,413 $728,000

Others Institutions Holding NBIX

# of Institutions

702

Shares Held

104M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.3B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track Joel Greenblatt's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Account